Pioglitazone, a ligand for peroxisome proliferator-activated receptor-γ acts as an inhibitor of colon cancer liver metastasis

Anticancer Research

Volumn 28, Issue 6 A, 2008, Pages 3593-3599

  Takano, Shota ^a   Kubota, Tetsuro ^a,b   Nishibori, Hideki ^a   Hasegawa, Hirotoshi ^a   Ishii, Yoshiyuki ^a   Nitori, Nobuhiro ^a   Ochiai, Hiroki ^a   Okabayashi, Koji ^a   Kitagawa, Yuko ^a   Watanabe, Masahiko ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Colon cancer; Liver metastasis; Pioglitazone

Indexed keywords

CIGLITAZONE; CYCLIN D1; CYCLOOXYGENASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; CELL STRAIN HT29; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; COLONIC NEOPLASMS; CYCLIN D1; CYCLOOXYGENASE 2; HCT116 CELLS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, SCID; PPAR GAMMA; THIAZOLIDINEDIONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149173507     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark E, Chambon P and Evans RM: The nuclear receptor superfamily: the second decade. Cell 83: 835-839, 1995.
2. Fajas L, Debrill MB and Auwerx J: Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol 27: 1-9, 2001.
3. Bull AW: The role of peroxisome proliferator-activated receptor-gamma in colon cancer and inflammatory bowel disease. Arch Pathol Lab Med 127: 1121-1123, 2003.
4. Coi IK, Kim YH, Kim JS and Seo JH: PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo. Invest New Drugs 26(3): 283-288, 2008.
5. Thompson EA: PPAR-gamma physiology and pathology in gastrointestinal epithelial cells. Moll Cells 24(2): 167-176, 2007.
6. Forman BM, Tontonz P, Chen J, Brun RP, Spiegelman BM and Evans RM: 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83(5): 803-812, 1995.
7. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC and Lehmann JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83(5): 813-819, 1995.
8. Lowell BB: PPARγ: An essential regulator of adipogenesis and modulator of fat cell function. Cell 99: 239-242, 1999.
9. Willson TM, Lehmann JM and Kliewer SA: Discovery of ligands for the nuclear peroxisome proliferator-activated receptor. Ann NY Acad Sci 804: 276-283, 1996.
10. Tontonz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM and Spiegelman BM: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor-gamma and the retinoid X receptor. Proc Natl Acad Sci USA 94: 237-241, 1997.
11. Yoshizumi T, Ohta T, Ninomiya I, Terada I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S and Miwa K: Thiazolodinedion, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 25: 631-639, 2004.
12. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partrige JB, Holden SA, Chen LB, Singer S, Fletcher C and Spiegelman BM: Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nature Med 4: 1046-1052, 1998.
13. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S and Matsuzawa Y: Peroxisome proliferator-activated receptor-gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 90: 75-80, 1990.
14. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I and Kohgo Y: Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 455: 135-139, 1999.
15. Yamauchi T, Watanabe M, Hasegawa H, Nishibori H, Ishii Y, Tatematsu H, Yamamoto K, Kubota T and Kitajima M: The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colon cancer. Anticancer Res 23: 245-250, 2003.
16. Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Ishii Y, Endo T, Kabeshima Y, Yorozuya K, Yamamoto K, Mukai M and Kitajima M: Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 45: 98-103, 2002.
17. Wang C, Fu M, D'Amico M, Albanese C, Zhou JN, Brownlee M, Lisanti MP, Chatterjee VKK, Lazar MA and Pestell RG: Inhibition of cellular proliferation through IκB kinase-independent and peroxisome proliferator-activated receptor γ-dependent repression of cyclin D1. Mol Cell Biol 21: 3057-3070, 2001.
18. Yamakawa-Karakida N, Sugita K, Inukai T, Goi K, Nakamura M, Uno K, Sato H, Kagami K, Barker N and Nakazawa S: Ligand activation of peroxisome proliferator-activated receptor γ induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity. Cell Death Differ 9: 513-526, 2002.
19. Gerhold DL, Liu F, Jiang G, Li Z, Xu J, Lu M, Sachs JR, Babchi A, Fridman A, Holder DJ, Doebber TW, Berger J, Elbrecht A, Moller DE and Zhang BB: Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor γ agonists. Endocrinology 143: 2106-2118, 2002.
20. Subbaramaiah K, Lin DT, Hart JC and Dannenberg AJ: Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. J Biol Chem 276: 12440-12448, 2001.
21. Wang C, Fu M, Sakamaki T and Pestell RG: Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology 145: 5439-5447, 2004.
22. Wendum D, Masliah J, Trugnan G and Flejou JF: Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch 445: 327-333, 2004.
23. Inoue H, Tanabe T and Umesono K: Feedback control of cyclooxygenase-2 expression through PPAR γ. J Biol Chem 275(36): 28028-28032, 2000.
24. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelestein B and Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutation in beta-catenin or APC. Science 275: 1787-1790, 1997.
25. Sunami E, Tsuno NH, Kitayama J, Saito S, Osada T, Yamaguchi H, Tomozawa S, Shibata Y and Nagawa H: Decreased synthesis of matrix metalloproteinase-7 and adhesion to the extracellular matrix proteins of human colon cancer cells treated with troglitazone. Surg Today 32: 343-350, 2002.
26. Motomura W, Nagamine M, Tanno S, Sawamukai M, Takahashi N, Kohgo Y and Okumura T: Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. J Gastroenterol 39: 461-468, 2004.